» Authors » Pierre Colin

Pierre Colin

Explore the profile of Pierre Colin including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 82
Citations 1334
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Saint F, Pasquier D, Villers A, Massa J, Colin P, Vankemmel O, et al.
Fr J Urol . 2024 Jul; 34(9):102675. PMID: 38969304
Objective: Information on bladder cancer (BC) according to the risk scoring for recurrence or progression in a general population is scarce despite its clinical relevance. The objective was to describe...
2.
Plouvier S, Marcq G, Vankemmel O, Colin P, Bonnal J, Leroy X, et al.
Int J Qual Health Care . 2024 May; 36(2). PMID: 38722033
Bladder cancer (BC) is a common malignancy in Europe and North America. Among BCs, muscle-invasive BCs (MIBCs) are distinguished, as they require aggressive treatment due to their spreading potential and...
3.
Couchoux T, Jaouen T, Melodelima-Gonindard C, Baseilhac P, Branchu A, Arfi N, et al.
Eur Urol Oncol . 2024 Mar; 7(5):1113-1122. PMID: 38493072
Background And Objective: Prostate multiparametric magnetic resonance imaging (MRI) shows high sensitivity for International Society of Urological Pathology grade group (GG) ≥2 cancers. Many artificial intelligence algorithms have shown promising...
4.
Touzani A, Fiard G, Barret E, Renard-Penna R, Salin A, Pradere B, et al.
Eur Urol Open Sci . 2022 Oct; 45:76-80. PMID: 36217451
PERFECT is a multicentre randomised controlled clinical trial that evaluates the efficiency of fusion magnetic resonance imaging-targeted biopsies in the transperineal (TP) versus transrectal (TR) approach in terms of the...
5.
Aouni J, Bacro J, Toulemonde G, Colin P, Darchy L
Ther Innov Regul Sci . 2021 Apr; 55(4):818-840. PMID: 33851358
Background And Objectives: Dose selection is a key feature of clinical development. Poor dose selection has been recognized as a major driver of development failure in late phase. It usually...
6.
Nassif E, Mlecnik B, Thibault C, Auvray M, Bruni D, Colau A, et al.
Cancers (Basel) . 2021 Feb; 13(3). PMID: 33525361
(1) Background-The five-year overall survival (OS) of muscle-invasive bladder cancer (MIBC) with neoadjuvant chemotherapy and cystectomy is around 50%. There is no validated biomarker to guide the treatment decision. We...
7.
Foerster B, Abufaraj M, Mari A, Seisen T, Bandini M, Schweitzer D, et al.
Clin Genitourin Cancer . 2020 Oct; 19(3):272.e1-272.e7. PMID: 33046411
Introduction: The objective of this study was to evaluate the performance of different tumor diameters for identifying ≥ pT2 upper tract urothelial carcinoma (UTUC) at radical nephroureterectomy. Patients And Methods:...
8.
Kocher N, Canes D, Bensalah K, Roupret M, Lallas C, Margulis V, et al.
Transl Androl Urol . 2020 Sep; 9(4):1786-1793. PMID: 32944541
Background: Radical nephroureterectomy (RNU) is the referent standard for managing bulky, invasive, or high grade upper-tract urothelial carcinoma (UTUC). The UTUC patient population, however, generally harbor medical comorbidities thereby placing...
9.
Roumiguie M, Comperat E, Chaltiel L, Nouhaud F, Verhoest G, Masson-Lecomte A, et al.
World J Urol . 2020 Jul; 39(11):4055-4065. PMID: 32666225
Purpose: To assess the association between PD-L1 expression and disease-free survival (DFS) in High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) patients treated with intravesical Bacillus Calmette-Guerin (BCG) instillations (IBI). Methods: Retrospective...
10.
Ouzzane A, Colin P
Surg Laparosc Endosc Percutan Tech . 2020 Jun; 30(5):e28-e29. PMID: 32487856
The wide and fast spread of COVID-19 around the world has led to a dramatic increase in the need for protection products both for carers and for populations. Surgical team...